Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews

Página do item simplificado
dc.citation.issue4
dc.citation.volumev. 32
dc.contributor.authorSchussel, Victor [UNIFESP]
dc.contributor.authorKenzo, Lucas [UNIFESP]
dc.contributor.authorSantos, Andreia [UNIFESP]
dc.contributor.authorBueno, Julia [UNIFESP]
dc.contributor.authorYoshimura, Ellen [UNIFESP]
dc.contributor.authorLatorraca, Carolina de Oliveira Cruz [UNIFESP]
dc.contributor.authorPachito, Daniela Vianna [UNIFESP]
dc.contributor.authorRiera, Rachel [UNIFESP]
dc.coverageHoboken
dc.date.accessioned2020-07-20T16:31:07Z
dc.date.available2020-07-20T16:31:07Z
dc.date.issued2018
dc.description.abstractNausea and vomiting are common and distressing adverse events of chemotherapy. This review focuses on the findings and quality of systematic reviews (SRs) of cannabinoids for chemotherapy-induced nausea and vomiting (CINV). Review of SRs, a systematic literature search, was conducted in several electronic databases and included SRs evaluating cannabinoids for CINV in cancer patients. Methodological quality and quality of reporting were evaluated by AMSTAR and PRISMA, respectively. Initial search retrieved 2,206 records, and 5 SRs were included. On the basis of findings of the sole SR judged as high methodological quality, cannabinoids seem to be more effective than placebo, equal to prochlorperazine for reducing CINV, and to be preferred by patients. The response to different combinations of antiemetic agents seems to be equal to 1 antiemetic alone. The average of AMSTAR score was 5, and the average of PRISMA score was 13.2. Cannabinoids represent a valuable option for treating CINV, despite the adverse events related to treatment, such as drowsiness and cognitive impairment. There is no good quality evidence to recommend or not the use of cannabinoids for CINV. More studies are still needed to evaluate the effectiveness of cannabinoids when compared with modern antiemetics.en
dc.description.affiliationUniv Fed Sao Paulo UNIFESP, Escola Paulista Med, Sao Paulo, SP, Brazil
dc.description.affiliationUniv Fed Sao Paulo UNIFESP, Evidence Based Hlth Program, Sao Paulo, SP, Brazil
dc.description.affiliationCochrane Brazil, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo UNIFESP, Escola Paulista Med, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo UNIFESP, Evidence Based Hlth Program, Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.format.extent567-576
dc.identifierhttp://dx.doi.org/10.1002/ptr.5975
dc.identifier.citationPhytotherapy Research. Hoboken, v. 32, n. 4, p. 567-576, 2018.
dc.identifier.doi10.1002/ptr.5975
dc.identifier.issn0951-418X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55718
dc.identifier.wosWOS:000429577800001
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofPhytotherapy Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectantiemeticsen
dc.subjectcannabinoidsen
dc.subjectchemotherapyen
dc.subjectnauseaen
dc.subjectsystematic reviewen
dc.subjectvomitingen
dc.titleCannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviewsen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Coleções
EPM - Artigos